Summary of Study ST001933

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001222. The data can be accessed directly via it's Project DOI: 10.21228/M8RH8X This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST001933
Study Title	Absolute quantification of plasma cytokines and metabolome reveals the glycylproline regulating antibody-fading in convalescent COVID-19 patients
Study Summary	COVID-19 pandemic has caused tremendous costs worldwide and is still threatening public health in the “new normal”. The association between neutralizing antibody levels and metabolic alterations in convalescent patients with COVID-19 is still poorly understood. In the present work, we conducted absolutely quantitative approach to profile the metabolomes in the plasma of the ordinary convalescent patients with antibody (CA), the convalescents of rapidly faded antibodies (CO) as well as the healthy subjects.
Institute	Hong Kong Baptist University
Last Name	Yang
First Name	Zhu
Address	OEW901, Oen Hall Building West Wing,, Ho Sin Hang Campus, Hong Kong Baptist University, Kowloon Tong, Kowloon, 999077, Hong Kong
Email	yangzhu@gmail.com
Phone	(+852)34115162
Submit Date	2021-09-30
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2022-07-25
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002023
Treatment Summary:	We classified the convalescent patients into the CA and CO groups according to the results of the ELISA test of anti-SARS-CoV-2 IgG following the manufacturer’s instructions. Briefly, 100 μL of diluted plasma samples (1:100 to 1: 800 dilution) was added to pre-coated plates, and the plates were then incubated at 37°C for 1 h. After washing, 100 μL of horseradish peroxidase (HRP)-conjugated RBD protein of SARS-CoV-2 was added into each well, followed by 30 more min of incubation at 37°C. After washing, the OD value at 450 nm (A450) was determined. The cutoff for negative was calculated by summing 0.090 and the average A450 of negative-control. A sample was determined negative when its A450 was below this cutoff value.

Treatment ID:

TR002023

Treatment Summary:

We classified the convalescent patients into the CA and CO groups according to the results of the ELISA test of anti-SARS-CoV-2 IgG following the manufacturer’s instructions. Briefly, 100 μL of diluted plasma samples (1:100 to 1: 800 dilution) was added to pre-coated plates, and the plates were then incubated at 37°C for 1 h. After washing, 100 μL of horseradish peroxidase (HRP)-conjugated RBD protein of SARS-CoV-2 was added into each well, followed by 30 more min of incubation at 37°C. After washing, the OD value at 450 nm (A450) was determined. The cutoff for negative was calculated by summing 0.090 and the average A450 of negative-control. A sample was determined negative when its A450 was below this cutoff value.